The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

• Published in: Arthritis research & therapy Vol. 12; no. 2; p. R63
• Main Authors: Becker, Michael A, Schumacher, H Ralph, Espinoza, Luis R, Wells, Alvin F, MacDonald, Patricia, Lloyd, Eric, Lademacher, Christopher
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.04.2010; BioMed Central
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol - therapeutic use; Care and treatment; Clinical trials; Comorbidity; Dose-Response Relationship, Drug; Drug therapy; Febuxostat; Female; Gout; Gout - blood; Gout - drug therapy; Gout - epidemiology; Gout Suppressants - therapeutic use; Humans; Hyperlipidemias - epidemiology; Hypertension - epidemiology; Hyperuricemia; Hyperuricemia - blood; Hyperuricemia - drug therapy; Hyperuricemia - epidemiology; Kidney Diseases - epidemiology; Male; Management; Middle Aged; Obesity - epidemiology; Research article; Thiazoles - therapeutic use; Treatment Outcome; United States - epidemiology; Uric Acid - blood; Uric acid metabolism; Young Adult; United States

The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) > or = 8.0 mg/dL in a six-month trial. Subjects (n = 2,269) were randomized to febuxostat 40 mg or 80 mg, or allopurinol 300 mg (200 mg...